- Home
- SKYE
as 12-27-2024 4:00pm EST
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 108.3M | IPO Year: | N/A |
| Target Price: | $18.67 | AVG Volume (30 days): | 209.5K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.25 - $19.41 | Next Earning Date: | 02-09-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Skye Bioscience Inc. Common Stock (SKYE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Diep Tuan Tu | SKYE | Chief Development Officer | Nov 15 '24 | Sell | $5.27 | 19,574 | $97,721.86 | 101,748 | |
| DHILLON PUNIT | SKYE | Chief Executive Officer | Nov 15 '24 | Sell | $5.27 | 82,910 | $413,924.74 | 329,823 | |
| ARSENAULT KAITLYN | SKYE | Chief Financial Officer | Nov 15 '24 | Sell | $5.27 | 43,396 | $216,652.44 | 209,548 | |
| Grayson Paul A. | SKYE | Director | Nov 15 '24 | Sell | $5.27 | 86,551 | $432,061.41 | 259,701 |
Latest Skye Bioscience Inc. Common Stock News
SKYE Breaking Stock News: Dive into SKYE Ticker-Specific Updates for Smart Investing
GlobeNewswire
9 days ago
Skye Bioscience to Present at J.P. Morgan Healthcare Conference
GlobeNewswire
a month ago
Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences
TipRanks
a month ago
Skye Bioscience achieved more than 50% targeted patient enrollment in CBeyond
GlobeNewswire
a month ago
Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor
GlobeNewswire
2 months ago
Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights
GlobeNewswire
2 months ago
Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model
GlobeNewswire
2 months ago
Skye Bioscience to Announce Third Quarter 2024 Results
GlobeNewswire
2 months ago
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
Compare SKYE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SKYE Skye Bioscience Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.